JPRN-jRCT2080220627未知2 期
Dose-Response Study of Ocrelizumab for Rheumatoid Arthritis.
适应症
试验速览
- 阶段
- 2 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Diagnosis of RA for >=6 months according to the revised 1987 ACR criteria for the classification of RA.
- •- Receiving methotrexate at a dose of 6 to 8 mg/week(oral) for >=12 weeks, with a stable dose for the last 4 weeks before treatment.
- •- Positive serum RF.
排除标准
- •- Rheumatic autoimmune disease other than RA, or Significant systemic involvement secondary to RA. Patients with secondary Sjogren's syndrome or secondary limited cutaneous vasculitis with RA are eligible.
- •- Functional Class IV as defined by the ACR Classification of Functional Status in RA.
- •- History of or current inflammatory joint disease other than RA or other systemic autoimmune disorder.
- •- Any surgical procedure within 12 weeks prior to or planned within 24 weeks after baseline.
研究者
相似试验
未知
3 期
ong-Term Treatment Study of Ocrelizumab for Rheumatoid ArthritisRheumatoid ArthritisJPRN-jRCT2080220736Chugai Pharmaceutical Co., Ltd.200
招募中
1 期
Exploratory study for the treatment of rheumatoid arthritis by eliminating dampnessRheumatoid ArthritisITMCTR2000003354Guangdong Provincial Hospital of Chinese Medicine
进行中（未招募）
1 期
on-inferiority study of ocrelizumab and rituximab in active multiplesclerosisMultiple sclerosisCTIS2024-514287-84-00Rigshospitalet600
招募中
3 期
Non-inferiority study of ocrelizumab and rituximab in active multiple
sclerosisMultiple sclerosis2024-514287-84-00Rigshospitalet600
招募中
4 期
Analysis of effectiveness of Ozoralizumab toward bone structure in rheumatoid arthritisRheumatoid arthritisJPRN-jRCTs071230067Kawakami Atsushi40